NCT06479759View on ClinicalTrials.gov

LM-108 Antibody Combination With Sintilimab for Locally Advanced or Metastatic Non-Small Cell Lung Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 12, 2024

Primary Completion Date

June 12, 2025

Study Completion Date

December 12, 2025

Conditions
NSCLCPD-1
Interventions
DRUG

LM-108 antibody and sintilimab

Cohort 1 receive LM-108 monoclonal antibody combined with sintilimab

DRUG

LM-108 antibody and sintilimab and chemotherapy

Cohort 2 receive LM-108 monoclonal antibody combined with sintilimab and chemotherapy for 4-6 cycles. LM-108 monoclonal antibody combined with sintilimab will be maintained

Trial Locations (1)

200000

RECRUITING

Shanghai Pulmonary Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Pulmonary Hospital, Shanghai, China

OTHER